Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia

doi:10.1016/0140-6736(91)91029-T

The Lancet

Volume 338, Issue 8764, 17 August 1991, Pages 399-403

https://doi.org/10.1016/0140-6736(91)91029-T Get rights and content

Abstract

The clinical relevance of cellular drug resistance in children with acute lymphoblastic leukaemia (ALL) is unknown. The relation between in-vitro sensitivity to chemotherapeutic drugs at initial diagnosis and long-term clinical outcome was investigated in 44 children with ALL. The short-term MTT assay was used to assess sensitivity to prednisolone, vincristine, colaspase (asparaginase), daunorubicin, and thioguanine (instead of mercaptopurine which is unstable in vitro). For vincristine and colaspase there was no difference in outcome (probability of continuous complete remission) between sensitive and resistant patients. However, the probability of continuous complete remission was significantly lower in patients with resistant cells than in those with sensitive cells for thioguanine (p<0·01), daunorubicin (p<0·02), and prednisolone (p<0·05). For prednisolone there was a significant worsening of the prognosis (p<0·05) from the extremely sensitive patients through an intermediate group to the most resistant group. The prognostic significance of cellular drug resistance was independent of white-blood-cell count, age, sex, and hepatosplenomegaly. Leukaemic cells from boys were more resistant to thioguanine than those from girls. Thus, the short-term highly efficient MTT assay can help to predict long-term response to chemotherapy in childhood ALL.

References (31)

We Evans et al.
Clinical pharmacology of cancer chemotherapy in children
Pediatr Clin North Am
(1989)
R. Pieters et al.
Adaptation of a rapid automated tetrazolium based (MTT-)assay for chemosensitivity testing in childhood leukemia
Cancer Lett
(1988)
Bg Campling et al.
Use of the MTT assay for rapid determination of chemosensitivity or human leukemic blast cells
Leuk Res
(1988)
Dl Kirkpatrick et al.
Chemosensitivity testing of fresh human leukemic cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay
Leuk Res
(1990)
R. Pieters et al.
In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions
Blood
(1990)
J. Mattern et al.
Clinical relevance of predictive tests for cancer chemotherapy
Cancer Treat Rev
(1982)
Ml Rothenberg et al.
Expression of the mdr-1/p-170 gene in patients with acute lymphoblastic leukemia
Blood
(1989)
Ajp Veerman et al.
Drug sensitivity assays in leukemia and lymphoma
Br J Haematol
(1990)
T. Hongo et al.
Anticancer drug sensitivity test using the short-term microplate culture and MTT dye reduction assay
Jpn J Cancer Chemother
(1987)
V. Santini et al.
In vitro chemosensitivity testing of leukemic cells: prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia
Haematol Oncol
(1989)

Jm Sargent et al.

Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia

Br J Cancer

(1989)

Pr Twentyman et al.

Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay

Br J Haematol

(1989)

R. Pieters et al.

Comparison of a rapid automated tetrazolium based (MTT-)assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia

Br J Cancer

(1989)

T. Hongo et al.

An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia

Cancer

(1990)

R. Pieters

Drug resistance in childhood leukemia

(1991)

Cited by (224)

Mutual antagonism between glucocorticoid and canonical Wnt signaling pathways in B-cell acute lymphoblastic leukemia
2023, Blood Advances
Altered Metabolism of Leukemic Cells: New Therapeutic Opportunity
2018, International Review of Cell and Molecular Biology
The cancer metabolic program alters bioenergetic processes to meet the higher demands of tumor cells for biomass production, nucleotide synthesis, and NADPH-balancing redox homeostasis. It is widely accepted that cancer cells mostly utilize glycolysis, as opposed to normal cells, in which oxidative phosphorylation is the most employed bioenergetic process. Still, studies examining cancer metabolism had been overlooked for many decades, and it was only recently discovered that metabolic alterations affect both the oncogenic potential and therapeutic response. Since most of the published works concern solid tumors, in this comprehensive review, we aim to summarize knowledge about the metabolism of leukemia cells. Leukemia is a malignant disease that ranks first and fifth in cancer-related deaths in children and adults, respectively. Current treatment has reached its limits due to toxicity, and there has been a need for new therapeutic approaches. One of the possible scenarios is improved use of established drugs and another is to introduce new druggable targets. Herein, we aim to describe the complexity of leukemia metabolism and highlight cellular processes that could be targeted therapeutically and enhance the effectiveness of current treatments.
A precision medicine approach to haematological malignancies
2017, The Lancet Haematology
Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance
2015, Pediatrics and Neonatology
Asparaginase is one of the most important chemotherapeutic agents against pediatric acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. The therapeutic efficacy (e.g., chemoresistance) and adverse effects of asparaginase (e.g., hypersensivity and pancreatitis) have been investigated over the past four decades. It was suggested early on that leukemic cells are resistant to asparaginase because of their increased asparagine synthetase activity. Afterward, other mechanisms associated with asparaginase resistance were reported. Not only leukemic cells but also patients themselves may play a role in causing asparaginase resistance, which has been associated with unfavorable outcome in children with ALL. This article will briefly review asparaginase therapy in children with ALL and comprehensively analyze recent reports on the potential mechanisms of asparaginase resistance.
Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance
2015, Biochemical and Biophysical Research Communications
Although previous studies attributed a pro-survival role to USP9X in human cancer, how USP9X affects B-cell acute lymphoblastic leukemia (B-ALL) remains unclear. Here, we found that USP9X is overexpressed in B-ALL cell lines and human patients. We investigated the role of USP9X in B-ALL and found that USP9X knockdown significantly reduced leukemic cell growth and increased spontaneous apoptosis, thereby improving survival in immunodeficient mice. These effects are partially mediated by the intrinsic apoptotic pathway, as we found that USP9X-knockdown leukemic cells displayed MCL1 down-regulation, with decreased BCL-2/BCL-XL levels and increased BAX levels. In addition, we demonstrated that USP9X inhibition negatively regulates mTORC1 activity toward its substrate S6K1. Clinically, USP9X inhibition sensitized glucocorticoid-resistant ALL cells to prednisolone; this observation reveals a potential avenue for improving the treatment of drug-resistant relapses. Collectively, our findings suggest that the combination of USP9X targeting and glucocorticoids treatment has attractive utility in B-ALL. This approach represents a potential strategy for promising combination therapies for lymphoid malignancies.
Utility of ASNS gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL
2023, Epigenetics

View all citing articles on Scopus

View full text

ORIGINAL ARTICLESRelation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia

Abstract

Pediatr Clin North Am

Cancer Lett

Leuk Res

Leuk Res

Blood

Cancer Treat Rev

Blood

Drug sensitivity assays in leukemia and lymphoma

Br J Haematol

Anticancer drug sensitivity test using the short-term microplate culture and MTT dye reduction assay

Jpn J Cancer Chemother

In vitro chemosensitivity testing of leukemic cells: prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia

Haematol Oncol

Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia

Br J Cancer

Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay

Br J Haematol

Comparison of a rapid automated tetrazolium based (MTT-)assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia

Br J Cancer

An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia

Cancer

Drug resistance in childhood leukemia

ORIGINAL ARTICLES
Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia